ESMO Daily Reporter
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
ESMO Daily Reporter
Oct 18, 2024, 15:13 |
Blog
Studies presented at MAP2024 showcase the potential of CTCs, exo-miRNA, cfRNA in Cancer Detection and Progression Prediction - ESMO
ESMO - European Society for Medical Oncology shared a post on LinkedIn: "Three studies presented at…
Oct 10, 2024, 14:20 |
Societies
Promising antitumour activity of new treatment modalities advanced solid tumours - ESMO
ESMO shared on LinkedIn: “Unleashing the power of immunotherapy in oncology is still challenging. While…
Sep 29, 2024, 14:41 |
Blog
Increasing the knowledge of pharmacologic interventions targeting cancer and treatment-related symptoms at ESMO24
ESMO posted on LinkedIn: "Well-designed multicenter randomised clinical trials are paramount to collect evidence and…
Sep 26, 2024, 17:57 |
Insight
Results from the ABIGAIL study presented at ESMO24
ESMO - European Society for Medical Oncology shared a post on LinkedIn: "At ESMO24 results…
Sep 17, 2024, 21:50 |
Blog
Late-breaking primary results from the DESTINYBreast-12 trial at ESMO24
ESMO posted on LinkedIn: "At ESMO24, late-breaking primary results from the DESTINYBreast-12 trial revealed substantial…
Sep 17, 2024, 16:30 |
Blog
Christian Rolfo: ESMO24 liquid biopsy research editorial by Umberto Malapelle
Christian Rolfo, Professor of Internal Medicine -Oncology at Ohio State University Comprehensive Cancer Center, shared a…
Sep 17, 2024, 14:34 |
Blog
Vivek Subbiah: Comments on the ESMO Presidential Symposium Precision Oncology trials and DRUP-like trials
Vivek Subbiah shared a post on LinkedIn by ESMO adding: "Hot off the press Read…
Sep 16, 2024, 10:25 |
Societies
The efficacy benefits of radioisotopes in metastatic castration-resistant prostate cancer - ESMO
ESMO shared on LinkedIn: "At ESMO24, Late-Breaking Abstracts provide evidence for the efficacy benefits of…
Sep 15, 2024, 10:47 |
Societies
No role for pre-operative CRT in the treatment of operable Gastric cancer - ESMO
ESMO shared on LinkedIn: "Final results presented at ESMO24 from the phase III TOPGEAR trial…
Sep 15, 2024, 09:40 |
Societies
The final analysis of the KEYNOTE-811 trial presented at ESMO24
ESMO shared on LinkedIn: "As presented at ESMO24, the final analysis of the KEYNOTE-811 trial…
Sep 14, 2024, 12:25 |
Blog
Young patients with breast cancer have unique needs that must be addressed - ESMO
ESMO - European Society for Medical Oncology posted the following on LinkedIn: “Young patients with…
Sep 5, 2024, 13:47 |
Societies
Is Gender Equity still an issue in oncology? - ESMO
ESMO shared on LinkedIn: "Is Gender Equity still an issue in oncology? New findings from the…
Aug 29, 2024, 16:04 |
Societies
Creating a favourable framework for tissue-agnostic research - ESMO
ESMO shared on LinkedIn: "Advances in Precision Oncology are reshaping Cancer Care, moving towards a…
Aug 25, 2024, 20:23 |
Blog
First recommendations from the ESMO/ SIOG about Geriatric Assessment and Personalised Care
ESMO posted on LinkedIn: "Cancer in older adults: Geriatric Assessment and management plays a crucial…
Aug 16, 2024, 14:26 |
Insight
Dario Trapani’s perspective on global cancer control and current cancer trends
Dario Trapani, Medical oncologist at IEO European Institute of Oncology, shared a post by ESMO…
Jul 26, 2024, 10:09 |
Blog
ESMO - We can take steps to balance the risks and benefits of sunscreen use
ESMO shared on LinkedIn: “Summer alert: Sunscreens are crucial for protecting our skin from harmful…
Jul 16, 2024, 05:27 |
Insight
Newly published ESMO Recommendations on genomics test results for Solid Cancers
ESMO - European Society for Medical Oncology shared on LinkedIn: "How to interpret genomic testing…
Jul 5, 2024, 02:30 |
Drugs
Ipilimumab and Nivolumab for patients with unresected advanced Hepatocellular Carcinoma - ESMO
ESMO shared on LinkedIn: "Benefits reported for the combination of ipilimumab and nivolumab further expand…
Jul 2, 2024, 07:19 |
Societies
25 Posts You Should Not Miss From ESMOGI24!
ESMOGI24 took place as an onsite event in Munich, Germany, from 26 to 29 June…
Jun 29, 2024, 10:49 |
Societies
The role of gut microbiome in cancer at ESMOGI24
ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024,…
Jun 29, 2024, 06:16 |
Societies
Microbiome Research is reshaping colorectal cancer treatment
ESMO shared on LinkedIn: "ESMOGI24: Since the development of Colorectal Cancer (CRC) is intertwined with…
Jun 28, 2024, 13:42 |
Societies
NEST Trial highlighted by Myriam Chalabi
Pashtoon Kasi shared on LinkedIn: "NEST Trial highlighted by Myriam Chalabi. Link to the ESMO…
Jun 28, 2024, 13:15 |
Insight
The clinical utility of liquid biopsies detecting ctDNA in guiding treatment for patients with mCRC - ESMO
ESMO (European Society for Medical Oncology) shared on LinkedIn: "Data from two presentations at ESMOGI24…
Jun 28, 2024, 10:52 |
Societies
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
ESMO shared a post on LinkedIn: "ESMOGI24: Colorectal Cancer (CRC) can be classified into two…
Jun 28, 2024, 10:40 |
Societies
The final results of the KEYNOTE-585 study presented at ESMOGI24
ESMO shared on LinkedIn: "The final results of the KEYNOTE-585 study presented at ESMOGI24 suggest…
Jun 28, 2024, 08:19 |
Societies
15 Posts You Should Not Miss From The 1st Day of ESMOGI24
ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29…
Jun 27, 2024, 09:10 |
Insight
The promise of immuno-oncology in the neoadjuvant setting - ESMO
The European Society for Medical Oncology (ESMO) shared on LinkedIn: “The promise of immuno-oncology in…
Jun 26, 2024, 13:47 |
Societies
177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs
ESMO shared on LinkedIn: "ESMOGI24: Promising data from the phase III NETTER-2 study show that…
Jun 15, 2024, 07:40 |
Insight
Findings from a first-in-human phase I study investigating IBI363 - ESMO
ESMO shared on LinkedIn: "ESMO Virtual Plenary: Findings from a first-in-human phase I study investigating…
May 29, 2024, 04:01 |
Insight
ESMO Precision Medicine Working Group released NGS recommendations
ESMO shared on LinkedIn: "ESMO has just released recommendations for the use of next-generation sequencing (NGS)…
May 18, 2024, 01:12 |
Opinion
Results from the IMpassion132 trial presented at ESMO Breast 24
The European Society for Medical Oncology (ESMO) shared on LinkedIn: “Results from the IMpassion132 trial presented…
May 15, 2024, 13:47 |
Societies
Interview with Eric Van Cutsem and Zorana Maravic on the ESMO Daily Reporter - ESMO
The European Society for Medical Oncology (ESMO) shared on X: “While novel agents continue to…
Mar 1, 2024, 16:32 |
Blog
Yardena Samuels discusses how ongoing research is revisiting the classic neoantigen approach - The European Society for Medical Oncology (ESMO)
The European Society for Medical Oncology (ESMO) posted on LinkedIn: “ESMOTAT24: Novel antigens for cancer…
Oct 24, 2023, 14:57 |
Blog
ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO) shared on LinkedIn: "Positive outcomes in advanced or metastatic…
All:
34
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube